Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company specializing in novel serotonergic agonists (NSAs), announced that CEO Michael Halstead will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference. The conference, scheduled for September 14-16, 2026, in New York City, is a key event for investors seeking insights into emerging biotech companies. The fireside chat will be webcast live on September 14 at 9 a.m. EDT, with a replay available on the Events & Presentations page of Helus Pharma's investor relations website.
This appearance comes at a pivotal time for Helus Pharma, which is advancing a pipeline of proprietary NSAs designed to activate serotonin pathways and promote neuroplasticity. The company's lead candidate, HLP003, is in Phase 3 clinical development for the adjunctive treatment of major depressive disorder (MDD) and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. This designation underscores the potential of HLP003 to address a significant unmet need in MDD, a condition that affects millions worldwide and often fails to respond adequately to existing treatments.
Additionally, Helus Pharma is developing HLP004, a second NSA in Phase 2 for generalized anxiety disorder (GAD). The company's research portfolio extends to other investigational NSAs, reflecting a broad strategy to tackle various mental health conditions. The focus on NSAs is part of a growing trend in psychiatric medicine, where psychedelic-inspired compounds are being studied for their ability to produce rapid and sustained improvements in mood and anxiety disorders.
The significance of Helus Pharma's participation in the H.C. Wainwright conference lies in the exposure it provides to institutional investors and industry analysts. As the company prepares for potential regulatory milestones and clinical data readouts, securing investor confidence is crucial. The conference offers a platform for CEO Michael Halstead to articulate the company's vision, highlight clinical progress, and discuss future development plans.
Helus Pharma, the commercial operating name of Cybin Inc., founded in 2019, operates in Canada, the United States, the United Kingdom, and Ireland. The company's mission is to help minds heal by introducing NSAs that aim to provide durable improvements in mental health. With class-leading data, Helus Pharma intends to improve the treatment landscape for depression, anxiety, and other mental health conditions.
Investors and stakeholders can access the full press release for more details at https://ibn.fm/1HSIo. The latest news and updates regarding HELP are available in the company's newsroom at https://ibn.fm/HELP. For more information about Helus Pharma, visit www.helus.com.
The H.C. Wainwright conference is known for featuring promising biotech firms, and Helus Pharma's presence signals its emergence as a key player in the mental health space. As the company progresses with its late-stage trials, the outcomes could have profound implications for patients and the psychiatric drug market. The fireside chat will likely address topics such as clinical trial design, regulatory pathways, and the commercial potential of NSAs.
This announcement is particularly timely given the growing interest in alternative treatments for mental health disorders. Traditional antidepressants often take weeks to show effect and can have significant side effects. NSAs, by contrast, are designed to induce rapid neuroplasticity, potentially offering faster relief and longer-lasting benefits. If HLP003 succeeds in Phase 3, it could become a first-in-class adjunctive therapy for MDD, changing the standard of care.
Helus Pharma's commitment to innovation is evident in its extensive research portfolio and its global operational footprint. By participating in high-profile investment conferences, the company aims to attract the capital needed to advance its pipeline and bring these novel therapies to market. The webcast of the fireside chat will allow a broader audience, including retail investors, to gain insights into the company's strategy and progress.
As the conference approaches, all eyes will be on Helus Pharma's presentation, which could serve as a catalyst for increased attention from the investment community. With ongoing clinical trials and regulatory interactions, the company is positioned to make significant strides in the coming years, potentially offering new hope for individuals suffering from mental health conditions.
